TMCnet News

MBX Biosciences to Participate in Jefferies Healthcare Conference
[May 24, 2023]

MBX Biosciences to Participate in Jefferies Healthcare Conference

CARMEL, Ind., May 24, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of endocrine disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at the Jefferies Healthcare Conference on Thursday, June 8th, 2023, at 2:30 p.m. Eastern Time and will host 1-on-1 investor meetings.

About MBX Biosciences

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company pioneering Precision Endocrine Peptide™ (PEP™) therapeutic candidates to help people with endocrine disorders live fuller and healthier lives. MBX is advancing a pipeline of PEPs for clinically validated targets designed to deliver superior pharmaceutical properties and overcome key limitations of native peptide therapeutics. MBX 2109, its lead product candidate in development for the treatment of hypoparathyroidism (HP), is currently ina Phase 1 clinical trial. The company is supported by leading life science investors including Frazier Life Sciences, New Enterprise Associates, Norwest Venture Partners, OrbiMed, RA Capital Management and Wellington Management. MBX is based in Carmel, Indiana. To learn more, please visit the company website at and follow us on LinkedIn and Twitter.

Media Inquiries:

Ian Stone
Evoke Canale
[email protected]

Investor Inquiries:

Irina Koffler
LifeSci Advisors
[email protected]

Primary Logo

[ Back To's Homepage ]